Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisinin + artesunate is a combination of two antimalarial agents, both belonging to the artemisinin class derived from the plant Artemisia annua. Artemisinin is a sesquiterpene lactone with potent and rapid action against Plasmodium species, while artesunate is a semi-synthetic derivative of artemisinin designed for improved solubility and bioavailability. Both drugs act primarily by generating reactive oxygen species that damage parasite proteins and membranes after activation by heme or ferrous iron within infected erythrocytes. This combination would provide an extremely rapid reduction in parasite biomass due to their similar mechanisms but does not represent standard clinical practice, as current guidelines recommend combining an artemisinin derivative with a longer-acting partner drug to prevent recrudescence and resistance[3][4][8]. The primary indication for both drugs individually is the treatment of malaria, particularly caused by Plasmodium falciparum.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisinin + artesunate.